Overig
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
- Vak
- Instelling
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
[Meer zien]Voorbeeld 1 van de 3 pagina's
Voorbeeld 1 van de 3 pagina's
In winkelwagen
In winkelwagen
Verkoper
Volgen
ACTUALSTUDY
Ontvangen beoordelingen
Voorbeeld van de inhoud
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with MixedHyperlipidemia
May 28, 2024
- Plozasiran significantly lowered triglyceride levels with commensurate reductions in APOC3, non-HDL-C, and remnant cholesterol
- Data presented at European Atherosclerosis Society 92nd Congress and simultaneously published in the New England Journal of Medicine
PASADENA, Calif.--(BUSINESS WIRE)--May 28, 2024-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the
Phase 2b double blind, randomized MUIR study of investigational plozasiran (formerly ARO-APOC3) in patients with mixed hyperlipidemia. Treatment
with plozasiran in the MUIR study achieved reductions in triglyceride rich lipoproteins, a genetically validated target associated with increased risk of
atherosclerotic cardiovascular disease (ASCVD)1,2. These data were presented in an oral presentation today at the European Atherosclerosis Society
(EAS) 92nd Congress and simultaneously published in the New England Journal of Medicine.
“Plozasiran demonstrated potent and durable reductions of atherogenic lipoproteins, such as non-HDL-C, ApoB, and remnant cholesterol in the Phase
2 MUIR study that supports its further development in Phase 3 studies for patients with increased risk for ASCVD,” said Christie M. Ballantyne, M.D.,
Baylor College of Medicine, and Principal Investigator for the MUIR study. “Despite advances in treatment, patients with mixed hyperlipidemia have
elevated and persistent ASCVD risk due in part to high levels of atherogenic triglyceride rich lipoproteins. The promising results from treatment with
plozasiran in the MUIR study help to lay the groundwork for a more extensive study to potentially test whether plozasiran reduces ASCVD risk.”
Bruce Given, M.D., interim chief medical scientist at Arrowhead added, “Results from the MUIR study of plozasiran in patients with mixed
hyperlipidemia are encouraging and we are excited to present data at EAS and publish the results today in the New England Journal of Medicine. We
believe plozasiran shows promise in multiple diseases with substantial unmet need, including familial chylomicronemia syndrome, severe
hypertriglyceridemia, and mixed hyperlipidemia, and we are eager to further investigate plozasiran in additional clinical studies.”
Select MUIR Results
By silencing Apolipoprotein C-III (APOC3), plozasiran significantly reduced triglycerides and atherogenic triglyceride rich lipoproteins and increased
HDL, across all dose levels at Week 24 in patients with mixed dyslipidemia.
At week 24, representing trough effect after 2 quarterly doses, plozasiran treatment was associated with placebo adjusted reductions in triglycerides of
-50%, -56%, and -62% (all p<0.001) at the 10, 25, and 50 mg doses, respectively. Fasting triglyceride levels were normalized (achieved levels below
150 mg/dL) in most patients (79-92%) randomized to a treatment arm. Commensurate reductions in APOC3 of -57%, -73%, and -79%, with strong
positive correlations with changes in triglyceride levels were observed.
Changes in other atherogenic lipoprotein parameters were also observed. At week 24, for the quarterly doses of 10, 25, and 50 mg, the following
placebo adjusted changes were observed: non-HDL-C levels -17%, -18%, and -24%; apoB levels -10%, -13%, and -19%; and remnant cholesterol
levels -43%, -49%, and -48% with strong correlations with changes in triglyceride levels.
Safety and Tolerability
Plozasiran demonstrated a favorable safety profile in the MUIR study. The overall rates of occurrence of treatment-emergent adverse events (TEAEs)
and discontinuations were similar for plozasiran and placebo throughout the 48 weeks of observation. Observed adverse events generally reflected
the comorbidities and underlying conditions of the study population. TEAEs occurring in 5 or more patients were COVID-19, worsening glycemic
control, upper respiratory tract infection, urinary tract infection, headache, and bronchitis.
Arrowhead is also presenting data from the SHASTA-2 study of plozasiran and the ARCHES-2 study of zodasiran (formerly ARO-ANG3) at EAS.
Details about the EAS presentations are listed below.
European Atherosclerosis Society (EAS) 92nd Congress – May 26-29, 2024
Title: PLOZASIRAN (ARO-APOC3), DECREASES APOC3 AND TRIGLYCERIDES (TG) IN PATIENTS WITH MIXED DYSLIPIDEMIA: MUIR
FINAL RESULTS
Date/Time: May 28, 2024, 12:04 p.m. CEST
Presenter: Christie M Ballantyne, M.D.
Session: New Therapeutics
Title: PLOZASIRAN (ARO-APOC3), AN INVESTIGATIONAL RNAI THERAPEUTIC, DEMONSTRATES PROFOUND AND DURABLE
REDUCTIONS IN APOC-3 AND TRIGLYCERIDES (TG) IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SHTG), SHASTA-2
FINAL RESULTS
Date/Time: May 28, 2024, 2:49 p.m. CEST
Presenter: Daniel Gaudet, M.D., Ph.D.
Session: SaaG Session: The Enigmas of TG-rich Lipoproteins
Title: ZODASIRAN SILENCES HEPATIC ANGPTL3 LEADING TO DEEP AND DURABLE REDUCTIONS IN ATHEROGENIC LIPIDS AND
LIPOPROTEINS IN MIXED DYSLIPIDEMIA PATIENTS: FINAL RESULTS FROM ARCHES-2, DOUBLE-BLIND PERIOD
Date/Time: May 29, 2024, 11:30 a.m. CEST
Presenter: Robert Rosenson, M.D.
Session: Late Breaker Session 2: New Therapeutic Agents
Presentation material may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website after each
presentation concludes.
Dit zijn jouw voordelen als je samenvattingen koopt bij Stuvia:
Bewezen kwaliteit door reviews
Studenten hebben al meer dan 850.000 samenvattingen beoordeeld. Zo weet jij zeker dat je de beste keuze maakt!
In een paar klikken geregeld
Geen gedoe — betaal gewoon eenmalig met iDeal, Bancontact of creditcard en je bent klaar. Geen abonnement nodig.
Focus op de essentie
Studenten maken samenvattingen voor studenten. Dat betekent: actuele inhoud waar jij écht wat aan hebt. Geen overbodige details!
Veelgestelde vragen
Wat krijg ik als ik dit document koop?
Je krijgt een PDF, die direct beschikbaar is na je aankoop. Het gekochte document is altijd, overal en oneindig toegankelijk via je profiel.
Tevredenheidsgarantie: hoe werkt dat?
Onze tevredenheidsgarantie zorgt ervoor dat je altijd een studiedocument vindt dat goed bij je past. Je vult een formulier in en onze klantenservice regelt de rest.
Van wie koop ik deze samenvatting?
Stuvia is een marktplaats, je koop dit document dus niet van ons, maar van verkoper ACTUALSTUDY. Stuvia faciliteert de betaling aan de verkoper.
Zit ik meteen vast aan een abonnement?
Nee, je koopt alleen deze samenvatting voor $7.99. Je zit daarna nergens aan vast.
Is Stuvia te vertrouwen?
4,6 sterren op Google & Trustpilot (+1000 reviews)
Afgelopen 30 dagen zijn er 63950 samenvattingen verkocht
Opgericht in 2010, al 15 jaar dé plek om samenvattingen te kopen
Laatst bekeken door jou
Tentamen (uitwerkingen) ·
Med Surg Cardiovascular, Hematologic, and Lymphatic Systems Exam Questions And Answers 100% Verified
Tentamen (uitwerkingen) ·
Foreign Service Officer Test - World Affairs Correctly Answered Questions| UpToDate | Already Graded A+
Case uitwerking ·
Voorbeeld NCOI module Projectmanagement 2024, Projectplan Klanttevredenheidsonderzoek, Geslaagd cijfer 8,5
Voordeelbundel ·
Cope Health Scholars Bundled Exams Questions and Answers | 100% Verified and Updated 2024 | Graded A+
Tentamen (uitwerkingen) ·
COS 111 Final Exam Study Guide | 100 Questions with 100% Correct Answers | Verified | Latest Update 2024
Tentamen (uitwerkingen) ·
Summary Full Notes for Unit 3 Controlled Assessment - WJEC Applied Diploma in Criminology. VERIFIED 2025 new
Tentamen (uitwerkingen) ·
Nurs 251 Pharmacology Module Exam 5 portage learning/ABCnursing/Geneva College Questions and Answer
Tentamen (uitwerkingen) ·
ISC3701 Assignment 2 Answers | 14th May 2024 In-depth, Researched answers using the latest prescribed Book!
